Literature DB >> 10810389

The intestinal absorption of camptothecin, a highly lipophilic drug, across Caco-2 cells is mediated by active transporter(s).

E Gupta1, F Luo, A Lallo, S Ramanathan, V Vyas, E Rubin, P Sinko.   

Abstract

The intestinal transport properties and kinetics of camptothecin (CPT) through Caco-2 cell monolayers were characterized by determining concentration-, temperature-, and ATP-dependence as well as the effect of selected inhibitors. The absorptive permeability (Peff) of CPT was found to be concentration dependent and saturable (K(m) = 31.2 +/- 6.9 microM) indicating the involvement of a high affinity, low capacity transport system. CPT transport was also temperature dependent and inhibited by sodium azide plus 2-deoxyglucose, which deplete cellular ATP, further suggesting that an active, carrier-mediated transport system contributes to CPT absorption. Based on inhibition studies, the involvement of organic anion and cation transporters was implicated but not conclusively demonstrated. Total CPT transport decreased four fold with increasing pH from 5.5 to 8.5 indicating that CPT lactone contributed more significantly to overall CPT transport than CPT carboxylate. The results of these studies suggest that CPT absorption is mediated by multiple mechanisms including significant passive diffusion and active transport components. Since typical substrates for intestinal carriers are hydrophilic and charged, the involvement of putative absorptive carriers in the transport of CPT is a novel finding that may give insight into the erratic oral bioavailability of CPTs observed in the clinic.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10810389

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Human multidrug resistance associated protein 4 confers resistance to camptothecins.

Authors:  Quan Tian; Jing Zhang; Theresa May Chin Tan; Eli Chan; Wei Duan; Sui Yung Chan; Urs Alex Boelsterli; Paul Chi-Lui Ho; Hongyuan Yang; Jin-Song Bian; Min Huang; Yi-Zhun Zhu; Weiping Xiong; Xiaotian Li; Shufeng Zhou
Journal:  Pharm Res       Date:  2005-11       Impact factor: 4.200

Review 2.  Canonical and non-canonical barriers facing antimiR cancer therapeutics.

Authors:  Christopher J Cheng; W Mark Saltzman; Frank J Slack
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

3.  Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.

Authors:  S-J Lee; M Gounder; E H Rubin; Jong Ming Li; Zheming Gu; A Thalasila; E Loyer; A P Kudelka; C F Verschraegen
Journal:  Invest New Drugs       Date:  2008-07-04       Impact factor: 3.850

4.  Involvement of P-glycoprotein, multidrug resistance protein 2 and breast cancer resistance protein in the transport of belotecan and topotecan in Caco-2 and MDCKII cells.

Authors:  Hong Li; Hyo-Eon Jin; Wooyoung Kim; Yong-Hae Han; Dae-Duk Kim; Suk-Jae Chung; Chang-Koo Shim
Journal:  Pharm Res       Date:  2008-07-25       Impact factor: 4.200

5.  Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.

Authors:  William C Zamboni; Ramesh K Ramanathan; Howard L McLeod; Sridhar Mani; Douglas M Potter; Sandra Strychor; Lauren J Maruca; Cristi R King; Laura L Jung; Robert A Parise; Merrill J Egorin; Todd A Davis; Sharon Marsh
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.651

6.  In-vitro Cellular Uptake and Transport Study of 9-Nitrocamptothecin PLGA Nanoparticles Across Caco-2 Cell Monolayer Model.

Authors:  Katayoun Derakhshandeh; Gunther Hochhaus; Simin Dadashzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).

Authors:  Anita K Lalloo; Feng R Luo; Ailan Guo; Pankaj V Paranjpe; Sung-Hack Lee; Viral Vyas; Eric Rubin; Patrick J Sinko
Journal:  BMC Med       Date:  2004-05-04       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.